Trial Profile
Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation; Celgene International SARL
- 06 Dec 2023 This trial has been completed in Bulgaria, Hungary, and Poland (Date of the global end of the trial: 21-Nov-2023), according to the European Clinical Trials Database record.
- 05 Dec 2023 Status changed from active, no longer recruiting to completed.
- 03 Dec 2023 This trial has been completed in Germany, Bulgaria, and Poland, according to European Clinical Trials Database record.